- AZD3293 is an oral beta secretase cleaving enzyme (BACE) inhibitor that has been shown to significantly (and dose-dependently) decrease amyloid beta formation in phase I trials.
- AstraZeneca did the early clinical work on AZD3293 and is now partnering with Eli Lilly to further develop it. The team is determined to move rapidly into phase II/III trials.
- Lilly will pay AZ $500 million in development and regulatory milestones.
AstraZeneca and Eli Lilly have both been involved in Alzheimer’s disease (AD) research for many years and are well aware of the high rate of development failures in this therapeutic category. That's why the team is determined to usher the BACE inhibitor class into the therapeutic arsenal by rapidly advancing the clinical trial program.
The two companies will share all future costs and revenues post-launch.